Peptide reference entry
Caution. Still experimental; long-term safety and outcomes are still being studied.
Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors designed to combine appetite suppression with increased energy expenditure and hepatic fat oxidation. Phase 2 data show very high average weight loss compared with GLP-1 or dual agonists, but with a higher rate of some adverse events. It remains investigational, and long-term safety and cardiovascular outcomes are still being defined in ongoing trials.
Checked Jul 15, 2026.
Stack logs each dose you take, tracks what is left in the vial or bottle and shows how you kept to your plan. It records what you choose and does not recommend anything. Everything stays on your phone, with no account.
Get Stack on Google Play Peptide reconstitution calculatorThis entry summarises published information in plain language. It is not medical advice, a dosing recommendation or a substitute for a qualified healthcare professional. Many peptides are not approved for human use, and legal status varies by country. Check anything you rely on against primary sources.